Piper Sandler analyst David Amsellem reiterated a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback